

BAP1 stabilizes DIDO1

Supplementary Table 1. Sequences for siRNAs and primers used for qRT-PCR

Sequences for siRNAs		
Gene	Sequence	
si-BAP1#1	5'-CGUCCGUGAUUGAUGAUGAdTdT-3'	
si-BAP1#2	5'-CCAACUCUUGUGCAACUCAdTdT-3'	
si-DIDO1	5'-GCACAAGAGACUAGCGUCAGAGAAA-3'	
si-Control	5'-ACAGACUUCGGAGUACCGdTdT-3'	
Sequences for primers		
Gene	RT Forward	RT Reverse
BAP1	5'-AGGAGCTGCTGGCACTGCTGA-3'	5'-TTGTGGAGCCGGCCGATGCT-3'
DIDO1	5'-TTCCATCCAACTCTTGCCTTT-3'	5'-CCAAGAATTATATTCGGACGTGGTG-3'

Supplementary Table 2. Antibody list

Antibody epitope	Mono/polyclonal	Host	Source	Catalog No.	Application
BAP1	Monoclonal	Rabbit	Cell Signaling	D7W70	WB, IP
BAP1	Monoclonal	Mouse	Santa Cruz	sc-28383	IHC
DIDO1	Monoclonal	Mouse	Santa Cruz	sc-25264	WB, IP, IF, IHC
α -tubulin	Monoclonal	Mouse	Sigma	T5168	IF
γ -tubulin	Monoclonal	Rabbit	Abcam	ab179503	IF
ubiquitin	Monoclonal	Rabbit	Epitomics	6652-1	WB
Myc	Polyclonal	Rabbit	MBL	562	WB
HA	Monoclonal	Mouse	MBL	M180-3	WB, IF
FLAG	Monoclonal	Mouse	Sigma	F1804	WB
Actin	Monoclonal	Mouse	Sigma	A2228	WB

IF: immunofluorescence; IP: immunoprecipitation; IHC: immunohistochemistry; WB: Western blotting.

Supplementary Table 3. Patient characteristics and clinicopathological factors by ARRDC3 and YAP1 expression

	BAP1 neg	BAP1 pos	<i>p</i> value	DIDO1 neg	DIDO1 pos	<i>p</i> value
No. of patients	4	30		6	28	
Median age (years)	58.5	53.2		59.4	5	
Sex			0.649			0.891
Male	3	23		5	22	
Female	1	7		1	6	
Fuhrman grade			0.048			0.001
Low (G1/G2)	1	24		1	23	
High (G3/G4)	3	6		5	5	
Primary T stage			0.003			0.01
Low (pT1/pT2)	1	25		2	25	
High (pT3/pT4)	3	5		4	3	